Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist

Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist

Source: 
Fierce Biotech
snippet: 

Eli Lilly is planning to test its closely watched diabetes drug tirzepatide in a phase 2b nonalcoholic steatohepatitis (NASH) trial. The expansion is driven by midphase Type 2 diabetes data suggesting the dual GIP and GLP-1 receptor agonist improves markers associated with NASH.